Acasti Pharma

Activities: Pharmaceutical

Trending Articles

  1. RFK Jr. and the FDA devise plan to ensure infant formula safety and nutritional value Known as Operation Stork, Robert F. Kennedy Jr. and the FDA will address quality, safety, nutritional adequacy and research gaps associated with the US infant formula supply
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Study reveals ashwagandha's memory-boosting potential in adults with mild cognitive impairment Arjuna Natural's ashwangandha nutraceutical, Somin-On, may improve memory and other measures of cognitive function in older adults with mild cognitive impairment (MCI)
  3. Gelita to focus on concepts for protein fortification at HiE Bioactive collagen peptides, as well as special types of gelatin, play an important role in the development of dietary supplements
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Gluthianone: the key to healthy ageing? Kyowa Hakko's branded gluthianone nutraceutical can support healthy ageing through its antioxidant capacity, while also providing cellular, immune and liver health benefits
  5. Kensing debuts plant-based vitamin E ingredient, Sun E The company has added the upcycled vitamin E nutraceutical to its portfolio through the acquisition of Advanced Organic Materials

Upcoming event

Vitafoods Europe

20–22 May 2025 | Exhibition | Barcelona See all

Related Content

Ingredients

Aker BioMarine acquires all krill-related patents from Acasti Pharma

Norway-based Aker BioMarine has acquired all krill-related patents, equipment, and scientific data from Acasti Pharma as a settlement towards a contractual obligation of US$3.1m
Ingredients

Aker BioMarine and Acasti Pharma enter krill oil supply agreement

The partnership with NASDAQ-listed, biopharmaceutical innovator Acasti will see Aker supply krill oil as core ingredient for a new hypertriglyceridemia drug
Manufacturing

Acasti Pharma and CordenPharma announce large-scale production of CaPre with continuous manufacturing

CaPre is a potentially best-in-class omega-3 drug derived of krill oil and being developed for the treatment of patients with hypertriglyceridemia, a metabolic condition that contributes to the risk of cardiovascular disease and pancreatitis
Subscribe now